10-Q: Perrigo Narrows Losses, Boosts Operating Income

Perrigo Company plc significantly reduced its net loss and achieved positive operating income in the second quarter of 2025, driven by cost-cutting initiatives and lower impairment charges.

Summary

• Perrigo reported a net loss of $8.4 million for the three months ended June 28, 2025, a substantial improvement from a net loss of $108.4 million in the prior year period.
• Operating income turned positive, reaching $45.4 million for the three months ended June 28, 2025, compared to an operating loss of $26.5 million in the same period last year.
• Net sales for the three months decreased slightly by 0.9% to $1,056.3 million, primarily due to prior year divestitures and lower consumption in certain categories, partially offset by favorable foreign currency translation.
• For the six months ended June 28, 2025, net loss improved to $14.8 million from $106.4 million, and operating income was $92.3 million compared to a loss of $81.7 million in the prior year.
• The Consumer Self-Care Americas (CSCA) segment saw net sales decrease by 1.9% to $622.0 million for the three months, impacted by lower Digestive Health and Oral Care sales, but boosted by an 11.0% increase in Nutrition sales due to infant formula recovery.
• The Consumer Self-Care International (CSCI) segment's net sales increased by 0.7% to $434.3 million for the three months, benefiting from favorable foreign currency translation and improved supply of key products like Solpadeine and Physiomer.
• Operating expenses decreased significantly by $103.7 million for the three months and $171.2 million for the six months, largely due to the absence of prior year impairment charges and savings from Project Energize.
• Cash flow from operating activities increased to $11.4 million for the six months ended June 28, 2025, up from $8.1 million in the prior year.
• The company completed the sale of the Richard Bittner Business AG on April 11, 2025, for $14.4 million, resulting in a pre-tax loss of $1.6 million.
• A binding agreement was entered into on July 13, 2025, to sell the Dermacosmetics branded business for up to €327 million, with closing expected in Q1 2026.
• Perrigo continues to implement its Supply Chain Reinvention Program, targeting $200 million to $300 million in annual run-rate savings by end of fiscal year 2028, with $150 million to $200 million anticipated by end of 2025.
• Project Energize, a global investment and efficiency program, is expected to deliver annualized pre-tax savings of $140 million to $170 million by the end of 2026, with an anticipated reinvestment of $40 million to $60 million.
• The Nutrition Network Optimization project involves an investment of approximately $240 million over the next three years to optimize infant formula manufacturing, with recoupment expected within two years post-completion.
• The company is involved in various legal proceedings, including price-fixing lawsuits, securities litigation (with a $97.0 million class action settlement finalized), talcum powder, ranitidine, and acetaminophen cases.
• A $98 million payment was received from insurers in full satisfaction of D&O insurance coverage litigation settlement.
• Perrigo was in compliance with all covenants under its debt agreements as of June 28, 2025.

Sentiment

Score: 7

Explanation: While net sales declined slightly, the significant improvement in profitability (reduced net loss, positive operating income) and cash flow, coupled with progress on strategic initiatives and favorable resolutions in some legal matters, indicates a positive trajectory despite ongoing challenges. The company's focus on streamlining operations and divesting non-core assets is a strong strategic move.

Positives

• Net loss significantly reduced for both the three-month (from $108.4M to $8.4M) and six-month (from $106.4M to $14.8M) periods ended June 28, 2025.
• Operating income turned positive, reaching $45.4 million for the three months and $92.3 million for the six months ended June 28, 2025, compared to losses in the prior year.
• Operating expenses decreased substantially by $103.7 million (three months) and $171.2 million (six months) due to the absence of prior year impairment charges and savings from Project Energize.
• Cash flow from operating activities increased by $3.3 million to $11.4 million for the six months ended June 28, 2025.
• The Nutrition category in CSCA showed strong recovery, with a 11.0% increase in net sales for the three months, driven by a 25% increase in store brand infant formula sales.
• Improved supply of key products like Solpadeine and Physiomer contributed to increased sales in the Pain and Sleep-Aids and Upper Respiratory categories in CSCI.
• Successful dismissal of all claims against the company in the Ranitidine MDL based on federal preemption and scientific causation, with settlements in principle for California and Illinois state court lawsuits.
• The Phenylephrine bellwether complaint was dismissed in its entirety, with claims preempted by federal law and RICO claims lacking standing.
• A favorable resolution was reached in the IRS audit of Athena Neurosciences, LLC, with an immaterial impact on financial statements.
• The D&O insurance coverage litigation was settled, resulting in a $98 million payment received by the company.
• Perrigo was in compliance with all financial covenants under its debt agreements as of June 28, 2025.

Negatives

• Overall net sales decreased by 0.9% for the three months and 2.2% for the six months ended June 28, 2025, primarily due to prior year divestitures and lower consumption in certain categories.
• Gross profit percentage decreased by 260 basis points to 34.4% for the three months ended June 28, 2025, impacted by divested businesses, isolated production variability in infant formula, and lower manufacturing efficiencies.
• CSCA net sales declined by 1.9% for the three months, driven by lower consumption and pricing of proton pump inhibitors in Digestive Health and lost distribution of lower margin products in Oral Care.
• Bad debt expense was recognized primarily related to a customer bankruptcy during the three months ended June 28, 2025.
• Cash and cash equivalents decreased to $454.2 million as of June 28, 2025, from $558.8 million at December 31, 2024.
• The company recorded a pre-tax loss of $1.6 million from the sale of the Richard Bittner Business AG.
• Ongoing legal proceedings, particularly price-fixing lawsuits and remaining securities opt-out cases, continue to pose potential liabilities and require significant legal defense.

Risks

• Macroeconomic uncertainty, including impacts from inflation, interest rates, volatile foreign currency exchange rates, tariffs, political unrest, and legislative/regulatory changes, could reduce sales or erode operating margins.
• Supply chain disruptions, exacerbated by armed conflict (e.g., war in Ukraine, Middle East conflicts), trade and economic sanctions, and disease, could negatively impact business operations.
• Current and future impairment charges may be recognized if the carrying amount of specific assets is determined not to be recoverable from expected future cash flows.
• Competition from other industry participants, some with greater marketing resources or larger market shares, could impact market position and profitability.
• Pricing pressures from customers and consumers may adversely affect revenue and margins.
• Resolution of uncertain tax positions and related litigation, particularly the omeprazole issue, could result in additional tax liability ranging from $25.0 million to $128.0 million, not including interest and penalties.
• Ongoing or future government investigations and regulatory initiatives, especially from the FDA regarding infant formula safety and compliance, could lead to increased costs and operational disruptions.
• Potential costs and reputational impact from product recalls or sales halts could harm the business.
• Adverse changes to U.S. and foreign tax, healthcare, and other government policies could negatively affect financial results.
• Fluctuations in currency exchange rates and interest rates can significantly impact net sales, net earnings, and cash flows.
• Potential costs or liabilities incurred or retained in connection with past divestitures (e.g., Rx business, HRA Rare Diseases Business, Hospital and Specialty Business) may exceed estimates.
• The ability to execute and achieve the desired benefits of announced cost-reduction efforts and other strategic initiatives, including restructuring programs, may not be fully realized.
• Adverse results with respect to pending litigation, including price-fixing, securities, talcum powder, and acetaminophen cases, could have a material adverse impact on operating results, cash flows, and liquidity.
• Inability to mitigate increased costs from new or additional tariffs, particularly on products and materials sourced from China, could materially increase cost of goods sold.
• The Foreign Trade Zone Board could revoke the sub-zone designation or further limit its use, leading to increased duties.
• Non-compliance with anti-corruption, anti-bribery, and economic sanctions laws could result in governmental investigations, substantial fines, and other penalties.

Future Outlook

Perrigo anticipates recouping its investment in the Nutrition Network Optimization project within two years post-completion. The company estimates a gross increase to global cost of goods sold in the fourth quarter of 2025 of approximately $10 million to $20 million due to tariffs, with a full-year impact of $50 million to $60 million, which it plans to offset through strategic pricing, insourcing, and supply chain actions. Management believes its existing global tax strategies will adequately address the OECD's Pillar Two framework without significantly affecting its effective tax rate or overall financial position. The outcome of the omeprazole tax litigation could result in additional tax liability of $25 million to $128 million for future tax years. The sale of the Dermacosmetics branded business is expected to close in the first quarter of 2026. Management believes current operations and borrowing resources are sufficient for both short-term and long-term capital requirements.

Management Comments

• Our vision is 'To Provide The Best Self-Care For Everyone' and our purpose is 'Make Lives Better Through Trusted Health and Wellness Solutions, Accessible To All'.
• Our unique competency is to deliver health and wellness solutions across multiple price and value tiers that improve access and choice for consumers.
• Perrigo's broad offerings are well diversified across several major product categories as well as across geographies, primarily in North America and Europe with no one product representing more than 5% of total revenue.
• Our plan to drive cash flow and total shareholder return is anchored behind its Three-S plan: Stabilizing Consumer Self-Care Americas store brand and infant formula businesses; Streamlining the global portfolio, enterprise operating model and Consumer Self-Care International business; and Strengthening what is working by prioritizing and increasing investments behind key High-Grow brands.
• All planned large-scale manufacturing plant resets have been completed, we have implemented quality enhancements, including further protocol, process and procedural improvements at the site level, and all sites are producing reliable, quality-assured product.
• Our focus is now on recovering store brand share and returning critical SKUs back to the shelves for consumers who need high-quality, affordable infant formula, while managing the additional cost and production processes to comply with new regulatory requirements.
• We believe that our existing global tax strategies will adequately address any necessary adjustments to comply with Pillar Two without significantly affecting our effective tax rate or overall financial position.
• Management believes that our operations and borrowing resources are sufficient to provide for our short-term and long-term capital requirements.

Industry Context

Perrigo operates as a pure-play self-care company, a leader in the over-the-counter (OTC) market and private label products. The company's performance reflects the evolving consumer demand for accessible, valuable, and reliable health solutions. The infant formula market continues to be influenced by stringent regulatory changes, requiring significant investments in manufacturing and quality control. The broader macroeconomic environment, including inflation, interest rate volatility, and geopolitical conflicts, impacts global supply chains and operational costs across the consumer health sector. The pharmaceutical industry, in which Perrigo has historical ties through its divested Rx business, remains subject to complex and costly litigation, particularly concerning antitrust and product liability claims.

Comparison to Industry Standards

• No specific comparable companies, projects, or results are listed in the filing for direct comparison to industry standards or global benchmarks.

Management Changes

Corporate Governance

Legal Proceedings

• **Price-Fixing Lawsuits (Former Rx Business):** Ongoing multidistrict litigation (MDL No. 2724) alleging anticompetitive conduct for generic drugs. Classes certified for Clobetasol and Clomipramine (Perrigo dismissed from Clobetasol). Third Circuit accepted appeal of class certification decisions on June 17, 2025, staying district court proceedings. Humana, Inc. complaint selected as bellwether in second phase. Connecticut Attorney General's office lawsuit (overarching conspiracy) remanded to District of Connecticut, with summary judgment briefing ongoing until November 21, 2025. Canadian class action pending, motion to certify scheduled for October 2025. A loss accrual of $30.0 million is recorded for these claims, with a 50% recovery receivable.
• **Securities Litigation (U.S. 2015-2017 events):** The class action settlement for $97.0 million received final approval on September 5, 2024, and the case was terminated for Perrigo. Four opt-out cases in the District of New Jersey remain unresolved, with settlement discussions ongoing. An additional loss provision of $12.0 million (Q2 2025) and $17.3 million (YTD Q2 2025) was recorded for these remaining opt-out cases.
• **Securities Litigation (Israel Irish Tax events):** The settlement for the Israeli securities class action (Baton v. Perrigo) was approved by the Israeli Court on June 5, 2024, funded by insurance, and distribution to class members was completed in June 2025, ending the case.
• **Talcum Powder:** The company is named in approximately 205 individual product liability lawsuits alleging mesothelioma and lung cancer due to talcum powder. The company is vigorously defending these lawsuits, with over 70 trials scheduled for 2025 and 2026, though most are expected to be postponed. Two cases are set for trial in California in September or October 2025.
• **Ranitidine:** The company successfully moved to dismiss all claims against it in the MDL based on federal preemption and scientific causation. Appeals of these orders have been filed to the U.S. Court of Appeals for the 11th Circuit. The company has also won motions to dismiss at the state-court level in multiple states, and reached settlements in principle for an immaterial amount in Illinois and California state court lawsuits, expected to be fully funded by insurance. No active lawsuits against the company in respect of ranitidine remain at the trial court level.
• **Acetaminophen:** The company has not been named as a defendant in any complaints filed in the MDL. The Court granted defendants' motions to exclude plaintiffs' general causation expert witnesses, and appeals are proceeding in the Second Circuit.
• **Phenylephrine:** The Court dismissed the bellwether complaint in its entirety, finding all claims preempted by federal law and RICO claims lacking standing. An appeal has been filed to the Second Circuit, with appellate briefing fully submitted.
• **Insurance Coverage Litigation:** A settlement was reached on December 18, 2024, providing for a $98 million payment from insurers in full satisfaction of their remaining liability, and the litigation was dismissed.

Stakeholder Impact

• **Shareholders:** The significant reduction in net loss and improvement in operating income may positively impact shareholder confidence. The finalization of the $97.0 million securities litigation settlement removes a significant overhang, though remaining opt-out cases still pose a risk. The ongoing dividend payments continue.
• **Employees:** Restructuring programs (Project Energize, Supply Chain Reinvention, Nutrition Network Optimization) involve employee separation costs and are expected to result in a net reduction of approximately 6% of total roles, impacting employment stability for some. Management changes, including retirements and new appointments, reflect an evolving organizational structure.
• **Customers:** Lower net sales in some categories due to decreased consumption and lost distribution indicate challenges in customer relationships or market demand. Efforts to recover infant formula market share and return critical SKUs to shelves aim to improve customer satisfaction and product availability. Strategic pricing actions are planned to offset tariff impacts, which may affect customer costs.
• **Suppliers:** Supply chain disruptions due to geopolitical conflicts (Middle East) and inflationary pressures continue to impact costs. The company is engaging alternate suppliers as a precaution for Israel-based suppliers, potentially shifting business relationships.
• **Creditors:** Compliance with all debt covenants and successful debt refinancing activities demonstrate financial stability and responsible debt management, which is favorable for creditors. Credit ratings remain under review with negative outlooks from Moody's and Fitch, indicating potential future pressure.

Next Steps

• Ron Janish will assist Perrigo in the transition of his duties until his retirement on September 30, 2025.
• Matt Winterman will work closely with Ron Janish to ensure a smooth transition in global supply chain leadership.
• The third round of summary judgment motions in the Connecticut Attorney General case is scheduled to complete on November 21, 2025.
• The motion to certify the Canadian Class Action Complaint as a class proceeding is scheduled to be heard in October 2025.
• Settlement discussions are ongoing for the four remaining opt-out cases in the District of New Jersey securities litigation.
• Appeals before the Second Circuit for the Acetaminophen MDL are fully briefed, with oral argument likely scheduled for Fall 2025.
• Appellate briefing for the Phenylephrine MDL is fully submitted, awaiting a date for oral argument from the Second Circuit.
• Over 70 talcum powder trials are scheduled for the remainder of 2025 and 2026, with two cases set for trial in Alameda County, California, in September or October 2025.
• The sale of the Dermacosmetics branded business is expected to close during the first quarter of 2026.
• The held-for-sale measurement for the Dermacosmetics Business disposal group will be assessed during the third quarter of 2025.
• Perrigo plans to invest approximately $240 million into its infant formula production network over the next three years as part of the Nutrition Network Optimization project.
• Project Energize is expected to be substantially incurred by the end of 2026, aiming to deliver annualized pre-tax savings of $140 million to $170 million.
• The company will continue to monitor regulatory developments to ensure ongoing compliance with the OECD's Pillar Two framework.
• Perrigo is currently assessing the impact of the One Big Beautiful Bill Act (OBBBA) on its financial condition and results of operations.

Key Dates

Recommendation

While Perrigo demonstrates significant progress in improving its profitability, evidenced by a substantial reduction in net loss and a shift to positive operating income, the overall net sales continue to decline, albeit partially due to strategic divestitures. The company's ongoing restructuring and efficiency programs (Supply Chain Reinvention, Project Energize, Nutrition Network Optimization) are positive for long-term operational health and cost management. However, the persistent legal overhang from various lawsuits, particularly the price-fixing and talcum powder cases, represents a material contingent liability and source of uncertainty. The mixed financial performance, with strong cost control but continued top-line challenges in some segments, combined with the unresolved legal risks, suggests a 'hold' recommendation. Investors should monitor the company's ability to achieve sustainable revenue growth and successfully navigate its remaining legal challenges before considering a more aggressive stance.

Keywords

Perrigo, PRGO, self-care, OTC, consumer health, infant formula, supply chain, restructuring, Project Energize, divestiture, legal proceedings, antitrust, securities litigation, talcum powder, ranitidine, acetaminophen, phenylephrine, quarterly report, financial results